Lackluster Market? Not for These 10 Soaring Stocks

Page 9 of 9

1. Cidara Therapeutics, Inc. (NASDAQ:CDTX)

Cidara Therapeutics soared to nearly a decade high on Friday, as investors gobbled up shares following news that it is set to be acquired by pharmaceutical giant Merck for $9.2 billion.

At intra-day trading, Cidara Therapeutics, Inc. (NASDAQ:CDTX) soared to its highest price of $218.85, before trimming gains to finish the day just up by 105.41 percent at $217.71 apiece.

In a statement, Cidara Therapeutics, Inc. (NASDAQ:CDTX) said that it entered into a definitive agreement with Merck, under which the latter would acquire its shares at a price of $221.50 apiece through its subsidiary.

The companies expect to close the transaction in the first quarter of 2026.

The acquisition followed Cidara Therapeutics, Inc. (NASDAQ:CDTX) receipt of a fast track designation from the Food and Drug Administration for its drug candidate, CD388, which aims to prevent influenza in individuals at higher risk of complications.

The CD388 is currently being evaluated in a Phase 3 study among adult and adolescent participants who are at higher risk of developing complications from influenza.

While we acknowledge the potential of CDTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CDTX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.

Page 9 of 9